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Objectives: Recent randomized controlled trials have
shown that age significantly affects the outcome of carotid
revascularization. The purpose of this study is to utilize data
from the SVS Vascular Registry® (VR) to report the influ-
ence of age on the comparative effectiveness of CEA and
CAS.
Methods: VR collects provider-reported patient-data
using a web-based database. Patients were stratified based
on age and symptomatology. The primary endpoint was the
composite of death, stroke and myocardial infarction (MI)
at 30-days.
Results: As of 12/7/10, there were 1347-CEA and
861-CAS 65 years and 4169-CEA and 2536 CAS
65years. In both age groups, CAS was more likely to
have radiation or restenosis for disease etiology, be symp-
tomatic, and have higher cardiac comorbidities. In
65years, CAS had higher rates of mortality (1.97% vs
0.91%, p0.01), stroke (4.89% vs 2.52%, p0.01) and the
combined death/stroke/MI (7.14% vs 4.27%, p0.01). In
65years, the primary endpoint (5.23% CAS vs 3.56%
CEA, p0.065) approached statistical significance. Further
analyses showed that CAS in 65years was associated
with higher primary outcome rate in both symptomatic
(9.52% vs 5.27%, p0.01) and asymptomatic (5.27% vs
3.31%, p0.01) subgroups. For 65years, CAS had
higher combined death/stroke/MI (4.44% vs 2.10%,
p0.031) in asymptomatics but no difference in symp-
tomatics (6.00% vs 5.47%, p0.79). After risk adjust-
ment (Table 1), CAS. 65years were more likely to
reach the primary endpoint
Conclusions: Compared to CEA, CAS resulted in
inferior 30-day outcomes in symptomatic and asymptom-
atic patients 65years.
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Objectives: The objectives of this study were to define
variables that predict failure of femoral access for mesen-
teric arterial intervention. We evaluated the relationship
between anatomical and mural characteristics of the mes-
enteric vessels to determine the optimal access site for
successful percutaneous intervention.
Methods: A prospective database identified all pa-
tients who underwent an endovascular mesenteric inter-
vention from 2005-2010. Patient demographics, lesion
characteristics and operative details were analyzed. All
angiograms were reviewed for mesenteric vessel angula-
tion, tortuosity, lesion severity, and calcium score to
determine the necessary access site for intervention. All
patients had an initial attempt made through femoral
access (F), followed by brachial access (B) if technical
success was not achieved.
Results: 142 mesenteric arteries in 125 patients were
reviewed. Of these, 83 vessels underwent endovascular
treatment (50 Celiac, 33 SMA). The majority of these
patients were female (n57). 22 lesions were treated for
aneurysm (15 celiac, 7 SMA) and 61 for CMI (12%
CTO). 58 lesions were treated with F, while 24 required
B. Mean angulation of the mesenteric arteries requiring
F access was 48 degrees / 15 and 40 / 18 for
brachial (P0.03). Calcification at the origin did not
impact access site (22% F- severe calcium score; 14% B;
P.5). Presence of CTO predicted brachial route (24% B
vs 3.4% F, P.008). Complication rates (arterial repair,
hematoma) were higher in the B group (16% B vs 4% F,
P.05).
Conclusions: Severe angulation and CTO are associ-
ated with technical failure for mesenteric intervention via
transfemoral route. This is the first study to define factors
where brachial access is the optimal approach for a success-
ful endovascular intervention.
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CTO (%)
Mesenteric Vessel
Angulation
(Degree)
Severe Calcification
at Origin (%)
Primary Patency
Rate(%) - 12
months
Secondary Patency
Rate(%) - 12
months
Diabetes
(%)
Tobacco
(%)
Female
Gender (%)
Femoral Access 3.4 48 22 49 79 24 48 69
Brachial Access 24 40 14 78 88 16 40 68
P Value .008 .03 .5 .1 .2 .37 .63 .8
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Objectives: Renal artery stenting (RAS) improves blood
pressure (BP) control and renal function in some patients, but
others derive no clear benefit. Proponents of RAS contend
that RAS will preserve renal mass even if there is no improve-
ment in BP or renal function. Currently there are limited data
to support that notion. The purpose of this study was to assess
the longitudinal changes in renal volume after RAS.
Methods: The study cohort consisted of 35 patients
with longitudinal imaging available for renal volume quan-
tification. Renal volume was estimated as kidney length 
width depth/2 based on preoperative CTA orMRA. For
each patient, the clinical response of BP and renal function
to RAS was categorized according to modified AHA guide-
lines. Changes in renal volume were assessed using paired
nonparametric analyses.
Results: The median age of the cohort was 60 years
(interquartile range [IQR], 60-74 years). A favorable BP
response was observed in 10 of 35 patients (29%). At a
median interval between imaging studies of 18 months
(IQR, 10-31 months), ipsilateral renal volume was signifi-
cantly increased from baseline (147 vs. 135 cm3; P
0.025). This represents a 4% relative increase in ipsilateral
kidney volume from baseline. A significant negative corre-
lation between preoperative renal volume and the relative
change in renal volume postoperatively (r  0.42;
P0.0055) suggests that smaller kidneys experienced the
greatest gains in renal volume after stenting. It is notewor-
thy that the 25 patients with no change in BP or renal
function—clinical failures using traditional definitions—
experienced a 12% relative increase in ipsilateral renal vol-
ume after RAS.
Conclusions: These data lend credence to the belief
that RAS preserves renal mass. This benefit of RAS even
extends to those patients who would be considered treat-
ment failures by traditional definitions. It remains unknown
whether the changes in renal mass induced by RAS will
translate into more stable renal function over the
long-term.
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Objectives: Time is of essence while caring for patients
with ruptured aortic aneurysms (RAAA). Multiple factors
which are beyond the control of treating physician play a
role in provision of timely care to these critically ill patients.
We examined time line of various events and its impact on
the process improvement since the inception of a protocol
for patients with ruptured aortic aneurysms.
Methods: A protocol was instituted in August 2009
which included a dedicated team with easy accessibility to
referring hospitals to streamline the care pathway for pa-
tients with RAAA. A prospective data base was established
to record the door to treatment time for patients. Besides
patient demographics, mode of transfer, various timelines
including time spent at the referring facility to diagnosis,
transfer time, wait time at the receiving hospital and overall
time were analyzed. A comparative analysis using two
–sample Wilcoxon test was then made between patients
who were treated prior to group 1 (January 2008-August
2009) and after group 2 (August 2009-November 2010)
implementation of protocol.
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